BIOMAT Database Logo BIOMAT Database Logo

Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. 2006

Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard

UI MeSH Term Description Entries
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000069446 Atazanavir Sulfate An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS. 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester,Atazanavir,BMS 232632,BMS-232632,BMS-232632-05,BMS232632,CGP 73547,CGP 75136,CGP 75176,CGP 75355,CGP-73547,CGP-75136,CGP-75176,CGP-75355,CGP75136,CGP75176,CGP75355,Reyataz,232632, BMS,BMS 232632 05,BMS23263205,CGP73547
D000863 Antacids Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. Alkalinizing Agent,Antacid,Alkalinizing Agents,Agent, Alkalinizing,Agents, Alkalinizing
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D054328 Proton Pump Inhibitors Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. Proton Pump Inhibitor,Inhibitor, Proton Pump,Inhibitors, Proton Pump,Pump Inhibitor, Proton

Related Publications

Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
March 2007, HIV medicine,
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
July 2004, Journal of clinical pharmacology,
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
January 2013, PloS one,
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
June 2009, The Journal of antimicrobial chemotherapy,
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma.
September 2010, AIDS (London, England),
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients.
March 2017, International journal of antimicrobial agents,
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole.
May 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.
January 2015, Contraception,
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
July 2006, European journal of clinical pharmacology,
Jean-Baptiste Guiard-Schmid, and Jean-Marie Poirier, and Philippe Bonnard, and Jean-Luc Meynard
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
August 2010, AIDS (London, England),
Copied contents to your clipboard!